Benign Prostatic Hyperplasia News and Research

RSS

Thumbs down by experts on plans to make certain meds OTC

Government plans to make certain prescription-only drugs for common problems available over the counter have overwhelmingly been given the thumbs down by healthcare professionals, reveals a survey of readers of the influential Drug and Therapeutics Bulletin ( DTB ).

13 Jan 2009

AEterna Zentari completes recruitment for phase 3 trial with Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. has reported it has reached its goal of recruiting 500 patients for the safety study of the Phase 3 program in benign prostatic hyperplasia (BPH) with its flagship product candidate, cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist.

11 Dec 2008

Aspirin lowers PSA levels

The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is significantly associated with lower PSA levels, especially among men with prostate cancer, say researchers at Vanderbilt University.

16 Nov 2008

Saw Palmetto for enlarged prostate

Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.

6 Nov 2008

Bladder conditions - raising awareness

November is Bladder Health Month, and there's no better time to raise awareness of the bladder conditions that affect millions of patients, who often suffer in silence with common, treatable symptoms.

4 Nov 2008

Nymox nears completion of benign prostatic hyperplasia drug trial

Nymox Pharmaceutical Corporation has announced that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion.

23 Oct 2008

Mylan receives tentative FDA approval for generic versions of Benicar and Uroxatral

Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg and 40 mg/25 mg.

22 Oct 2008

FDA approves Rapaflo for treatment of symptoms due to benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Rapaflo (silodosin) capsules for the treatment of symptoms due to benign prostatic hyperplasia (BPH), a condition also known as an enlarged prostate.

12 Oct 2008

NIDDK publishes strategic plan for research into benign prostate

For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). The NIDDK Prostate Research Strategic Plan is the culmination of discussions and meetings among experts over the past two years in an effort to outline a strategic vision for research into these elusive and multi-faceted diseases.

27 Jul 2008

Microwave therapy for enlarged prostates can cause surges in blood pressure

Many men who receive microwave therapy for enlarged prostates experience significant surges in blood pressure that could raise their risk of a heart attack or stroke, according to new research findings published recently in Mayo Clinic Proceedings.

9 Apr 2008

Heart-healthy diet may also be good for the prostate

Men who eat a diet low in fat and red meat but high in vegetables and lean protein and who drink alcohol in moderation may not just be doing their hearts a favor.

14 Feb 2008

Pros, cons of finasteride to prevent prostate cancer should be considered

Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.

22 Jan 2008

Prostatitis - one of the most common urologic diseases in the U.S

Estimates on the number of males in the United States who will experience prostatitis during their lifetimes range up to 50 percent.

21 Jan 2008

Urinary complications in men over 45

As many as one in four men admitted to hospital with acute urinary retention will die within a year, finds a study published on bmj.com.

13 Nov 2007

Coping with urinary incontinence

For older adults, increased urinary frequency is fairly common.

26 Sep 2007

Barr confirms UROXATRAL patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sanofi- Aventis U.S. LLC in connection with its UROXATRAL (alfuzosin hydrochloride extended-release tablets), 10mg.

25 Sep 2007

Black men do not have more aggressive prostate cancer

A University of Minnesota study of prostate cancer tumors from Caucasian and African-American men has shown no evidence that the cancer is more aggressive in black men.

18 Sep 2007

Shrinkage of prostate led to overestimation of cancer risk in finasteride trial

Reanalysis of data from the first long-term randomized trial of a chemopreventive agent for prostate cancer shows that the excess prevalence of high-grade prostate cancer in the drug-treated group may be attributable to shrinkage of the prostate at the time of biopsy.

13 Sep 2007

Finasteride will cause little or no sexual dysfunction for most men who decide to take it

Men and their physicians need not hesitate to use a drug proven effective in preventing prostate cancer out of concern that it is likely to cause sexual dysfunction, say authors of a study conducted by the Southwest Oncology Group.

20 Jul 2007

Ranbaxy receives tentative FDA approval for Tamsulosin capsules

Ranbaxy Pharmaceuticals has announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Tamsulosin Hydrochloride Capsules, 0.4 mg.

23 Jun 2007